Globenewswireยท2025-09-15 11:14Core Insights - Class actions have been initiated for stockholders of Altimmune, Inc. and SelectQuote, Inc. with deadlines for lead plaintiff petitions approaching [1] Altimmune, Inc. (NASDAQ:ALT) - The class period for Altimmune is from August 10, 2023, to June 25, 2025, with a lead plaintiff deadline of October 6, 2025 [2] - On June 26, 2025, Altimmune announced disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, failing to achieve statistical significance in the primary endpoint of fibrosis reduction due to a higher-than-expected placebo response [2] - Following the announcement, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [3] SelectQuote, Inc. (NYSE:SLQT) - The class period for SelectQuote is from September 9, 2020, to May 1, 2025, with a lead plaintiff deadline of October 10, 2025 [3] - On May 1, 2025, the U.S. Department of Justice filed a complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to 2021 [3] - The complaint claims SelectQuote misled Medicare beneficiaries by stating it offered unbiased coverage comparisons while actually directing them to plans that paid SelectQuote the most, resulting in a stock price drop of $0.61, or 19.2%, to close at $2.56 per share on the same day [3][4]